Giorgio L Colombo1, Carlo Maurizio Montecucco2. 1. Department of Drug Sciences, University of Pavia, Pavia, Italy. 2. Division of Rheumatology, IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy.
Abstract
INTRODUCTION: The appearance of off-patent generic drugs in the world pharmaceutical market is a highly interesting fact from the socio-economic point of view. However, the scientific documentation supporting the potential clinical and economic benefits of a growing use of off-patent alendronate generic in clinical practice seems to be limited in Italy as yet. PATIENTS AND METHODS: Comparing differences in persistence and compliance between off-patent generic alendronate and off-patent brand alendronate originator (Fosamax ®) in real clinical practice. The retrospective analysis was carried out by using the administrative databases of five Local Healthcare Units (ASL - Aziende Sanitarie Locali) in the Lombardy Region, in Italy. RESULTS: The selected sample of 5 ASLs included 20,711 patients; the average age was 73 years, with no difference between the two groups. After 34 months of observation, the persistence and compliance were no statistically different between off-patent generic alendronate vs off-patent brand alendronate. Data on days in persistence varied between 316 (Brand) vs 362 (Generic). Patients' compliance varied in average between 0.70 (Brand) and 0.72 for generic group. CONCLUSIONS: Off-patent generic drugs appear to be a therapy option of choice in Italy as well, both for the National Health Service and for citizens. Off-patent generic drugs can bring about an increased efficiency in health systems and increase the percentage of population benefitting from a medical care plan.
INTRODUCTION: The appearance of off-patent generic drugs in the world pharmaceutical market is a highly interesting fact from the socio-economic point of view. However, the scientific documentation supporting the potential clinical and economic benefits of a growing use of off-patent alendronate generic in clinical practice seems to be limited in Italy as yet. PATIENTS AND METHODS: Comparing differences in persistence and compliance between off-patent generic alendronate and off-patent brand alendronate originator (Fosamax ®) in real clinical practice. The retrospective analysis was carried out by using the administrative databases of five Local Healthcare Units (ASL - Aziende Sanitarie Locali) in the Lombardy Region, in Italy. RESULTS: The selected sample of 5 ASLs included 20,711 patients; the average age was 73 years, with no difference between the two groups. After 34 months of observation, the persistence and compliance were no statistically different between off-patent generic alendronate vs off-patent brand alendronate. Data on days in persistence varied between 316 (Brand) vs 362 (Generic). Patients' compliance varied in average between 0.70 (Brand) and 0.72 for generic group. CONCLUSIONS: Off-patent generic drugs appear to be a therapy option of choice in Italy as well, both for the National Health Service and for citizens. Off-patent generic drugs can bring about an increased efficiency in health systems and increase the percentage of population benefitting from a medical care plan.
Authors: Douglas W Roblin; Richard Platt; Michael J Goodman; John Hsu; Winnie W Nelson; David H Smith; Susan E Andrade; Stephen B Soumerai Journal: Med Care Date: 2005-10 Impact factor: 2.983
Authors: John R Peters; Dena R Hixon; Dale P Conner; Barbara M Davit; Debra M Catterson; Cecelia M Parise Journal: Dermatol Ther Date: 2009 May-Jun Impact factor: 2.851
Authors: Jeffrey J Ellis; Steven R Erickson; James G Stevenson; Steven J Bernstein; Renee A Stiles; A Mark Fendrick Journal: J Gen Intern Med Date: 2004-06 Impact factor: 5.128
Authors: Giorgio L Colombo; Enrico Agabiti-Rosei; Alberto Margonato; Claudio Mencacci; Carlo Maurizio Montecucco; Roberto Trevisan Journal: PLoS One Date: 2013-12-18 Impact factor: 3.240